Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

✍ Scribed by Haller, Hermann; Ito, Sadayoshi; Izzo, Joseph L.; Januszewicz, Andrzej; Katayama, Shigehiro; Menne, Jan; Mimran, Albert; Rabelink, Ton J.; Ritz, Eberhard; Ruilope, Luis M.; Rump, Lars C.; Viberti, Giancarlo

• Book ID: 119955420
• Publisher: Massachusetts Medical Society
• Year: 2011
• Tongue: English
• Weight: 726 KB
• Volume: 364
• Category: Article
• ISSN: 0096-6762
• DOI: 10.1056/NEJMoa1007994

✦ Synopsis

A bs t r ac t

Conclusions

Olmesartan was associated with a delayed onset of microalbuminuria, even though blood-pressure control in both groups was excellent according to current standards. The higher rate of fatal cardiovascular events with olmesartan among patients with preexisting coronary heart disease is of concern. (Funded by Daiichi Sankyo; ClinicalTrials.gov number, NCT00185159.